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work is the first stage for determining the design of pharmacology 
genetics research.
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Introduction: Oxycodone undergoes a relatively complicated metab-
olism producing 3 main metabolites: noroxycodone, oxymorphone, 
and noroxymorphone. Among these metabolites, oxymorphone is 
highly related to the pharmacodynamic effect of oxycodone. It is 14 
times more potent than the parent compound, and its affinity for the 
µ opioid receptor is 3 times higher than morphine. Development of a 
whole-body physiologically based pharmacokinetic (PK) model is an 
approach to predict in vivo metabolism of oxycodone and PK profile 
of each metabolite in different drug–drug interaction (DDI) scenarios.
Patients (or Materials) and Methods: The Simcyp simulator was used 
as a platform and database for simulation of oxycodone’s metabolism 
in virtual healthy populations. Prior in vitro and in vivo data were 
combined to build an oxycodone model which was used to predict 
the PK profile in healthy volunteers. The incorporated parameters 
were optimized by a top-down approach based on the clinical trial 
conducted by Samer et al, where PK profile of 0.2 mg/kg single dose 
oxycodone and its 3 metabolites were monitored in 10 healthy male 
volunteers (n = 10) previously genotyped for CYP2D6 in 4 scenar-
ios (oxycodone administered alone or coadministered with CYP3A 
inhibitor ketoconazole (400 mg) and/or CYP 2D6 inhibitor quinidine 
(100 mg)) (Samer C, Daali Y et al. 2010). The PK data obtained in 
3 interaction scenarios of the latter clinical trial were used to test 
the built model. Simulated trials permitted to evaluate the impact of 
CYP3A and CYP2D6 inhibitions on the concentration–time profiles 
of oxycodone and 3 main metabolites. The simulated studies designs 
were closely matched with the clinical trial and the virtual popula-
tions (1 trial of 10 volunteers, and 10 trials of 10 volunteers) were set 
with the same proportion of each CYP2D6 phenotype as the clinical 
trial (7 extensive, 1 poor and 2 ultrarapid metabolisers).
Results: Pharmacokinetic profiles of oxycodone and 2 predominant 
metabolites (oxymorphone and noroxycodone) were closely simu-
lated by the model.
Mean values (SD).
Oxycodone, noroxycodone, and oxymorphone PK profiles were 
also concordant with the clinical study according to CYP2D6 
phenotypic groups. Obtained DDI magnitudes were also in agree-
ment with the clinical data. Noroxymorphone PK profile was less 
accurately predicted by the model.
Conclusion: The Simyp developped model for oxycodone is valuable 
to predict the metabolism of oxycodone and main metabolites, and 
to simulate DDI involving CYP 3A and 2D6.
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Introduction: Oxcarbazepine (OXC) is a drug indicated for the treat-
ment of partial seizures or generalized tonic-clonic seizures in adults 
and children. It undergoes rapid presystemic reduction with forma-
tion of the active metabolite 10-hydroxycarbazepine (MHD), which 
has a chiral center at position 10, with the enantiomers (S)-(+)- and 
R-(-)-MHD with similar antiepileptic effects. OXC and MHD are 
substrates of P-glycoprotein (Pgp), whereas verapamil is an inhibitor 
of Pgp expressed in various tissues, including the brain. This study 
aims to evaluate the influence of verapamil on the pharmacokinetics 
of OXC and MHD enantiomers in healthy volunteers.
Patients (or Materials) and Methods: The study was conducted in 2 
phases and included 12 adult healthy volunteers. In the Phase I, they 
were treated with 300 mg/12 hours OXC during 5 days. On the fifth 
day, after the last dose, serial blood samples were collected up to 12 
hours. In the Phase II, the same healthy volunteers were treated with 
OXC (300 mg/12 hours during 5 days) associated with verapamil (80 
mg/8 hours during 5 days). On the fifth day, after the last OXC dose, 
serial blood samples were collected up to 12 hours. Plasma concentra-
tions of OXC and MHD enantiomers were evaluated by LC-MS/MS 
coupled with a chiral phase Chiralcel® OD-H column. Pharmacokinetic 
analysis was performed using the software WinNonlin and statistical 
tests were conducted with the significance level set at P < 0.05.
Results: The following pharmacokinetic parameters for OXC were 
obtained in Phase I (median): maximum plasma concentration (Cmax) 
of 1.35 mg/mL in 1.0 hour, area under the plasma concentration 
versus time curve (AUC0–12) of 3.98 μ g·h/mL and half-life of 2.45 
hours. The kinetic disposition of MHD was enantioselective, with 
observation of a higher proportion for the enantiomer S-(+)-MHD 
compared with R-(-)-MHD (AUC0-12S-(+) / R-(-) of 4.10). Verapamil 
treatment (Phase II) decreased the mean residence time (3.83 vs 4.71 
hours) and the apparent volume of distribution (Vdárea /f’)(2.86 vs 
3.78 L/kg) of OXC. Concerning MHD enantiomers, the verapamil 
treatment increased Cmax, AUC and Css for both enantiomers.
Conclusion: Verapamil treatment reduced OXC Vdárea/f’ and 
increased AUC of both MHD enantiomers probably due to the Pgp 
inhibition.
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AUC24h (ng·min/mL) Cmax (ng/mL)
Observed Simulated Simulated Observed Simulated Simulated
n = 10 n = 10 n = 100 n = 10 n = 10 n = 100
Oxycodone 12,086 
(3184)
12,305 
(8002)
12,953 
(6088)
35.9 
(11.3)
32.2 
(14.8)
35.3 
(13.6)
Noroxycodone 7753 
(2127)
7101 
(4442)
7502 
(4875)
15.5 
(4.3)
14.3 
(6.7)
15.3 
(9.7)
Oxymorphone 232 
(142)
179 (145) 244 (267) 0.7 (0.4) 0.7 (0.7) 0.8 (0.7)
